Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Our study provides a robust preclinical rationale and mechanisms of action for using batiraxcept as a single agent or in combination with docetaxel or carboplatin to treat lethal metastatic prostate cancer.
Authors
- Quaovi H. Sodji (ORCID: https://orcid.org/0000-0002-9469-1388)
- Alexandra Lapat Polasko (ORCID: https://orcid.org/0000-0002-1892-0847)
- Erinn B. Rankin (ORCID: https://orcid.org/0000-0002-2045-2296)
- Eva Corey (ORCID: https://orcid.org/0000-0002-9244-3807)
- Hongjuan Zhao (ORCID: https://orcid.org/0000-0001-6083-0370)
- James D. Brooks (ORCID: https://orcid.org/0000-0003-4521-7505)
- Jiaoti Huang (ORCID: https://orcid.org/0000-0003-1195-1998)
- Mikkel Thy Thomsen (ORCID: https://orcid.org/0000-0001-6515-675X)
- Chun-Lung Chiu (ORCID: https://orcid.org/0000-0001-7514-9676)
- Vanessa Yang (ORCID: https://orcid.org/0009-0005-9072-6685)
- Yu Rebecca Miao (ORCID: https://orcid.org/0000-0002-5848-9924)
- J. Spencer Hauck (ORCID: https://orcid.org/0000-0003-1722-8709)
- Kaixuan Yang
- Ru M. Wen (ORCID: https://orcid.org/0000-0002-4141-7377)
- Eric E. Peterson (ORCID: https://orcid.org/0000-0002-5006-3865)
- Donna M. Peehl (ORCID: https://orcid.org/0009-0003-8592-7242)
- Dalin Zhang
- Zhengyuan Qiu
- Yi Wei (ORCID: https://orcid.org/0009-0005-4653-7617)
Institutions
- Duke University (US)
- Palo Alto University (US)
- University of California, San Francisco (US)
- University of Washington (US)
- Aarhus University (DK)
- Aarhus University Hospital (DK)
- University of Oxford (GB)
- Stanford Medicine (US)
- Science Oxford (GB)
- Stanford University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3028
- Citations
- 2
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- U.S. Department of Defense
- National Cancer Institute